These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 27190382)

  • 1. Systemic complement activation and complement gene analysis in enterohaemorrhagic Escherichia coli-associated paediatric haemolytic uraemic syndrome.
    Ahlenstiel-Grunow T; Hachmeister S; Bange FC; Wehling C; Kirschfink M; Bergmann C; Pape L
    Nephrol Dial Transplant; 2016 Jul; 31(7):1114-21. PubMed ID: 27190382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eculizumab in the treatment of Shiga toxin haemolytic uraemic syndrome.
    Walsh PR; Johnson S
    Pediatr Nephrol; 2019 Sep; 34(9):1485-1492. PubMed ID: 30058046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new era in the diagnosis and treatment of atypical haemolytic uraemic syndrome.
    Westra D; Wetzels JF; Volokhina EB; van den Heuvel LP; van de Kar NC
    Neth J Med; 2012 Apr; 70(3):121-9. PubMed ID: 22516576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypertension and mild chronic kidney disease persist following severe haemolytic uraemic syndrome caused by Shiga toxin-producing Escherichia coli O104:H4 in adults.
    Derad I; Obermann B; Katalinic A; Eisemann N; Knobloch JK; Sayk F; Wellhöner P; Lehnert H; Solbach W; Süfke S; Steinhoff J; Nitschke M
    Nephrol Dial Transplant; 2016 Jan; 31(1):95-103. PubMed ID: 26180049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders.
    Wehling C; Amon O; Bommer M; Hoppe B; Kentouche K; Schalk G; Weimer R; Wiesener M; Hohenstein B; Tönshoff B; Büscher R; Fehrenbach H; Gök ÖN; Kirschfink M
    Clin Exp Immunol; 2017 Feb; 187(2):304-315. PubMed ID: 27784126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases.
    Nester CM; Brophy PD
    Curr Opin Pediatr; 2013 Apr; 25(2):225-31. PubMed ID: 23486421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of children with Shiga toxin-associated haemolytic uraemic syndrome treated with eculizumab: a matched cohort study.
    Monet-Didailler C; Chevallier A; Godron-Dubrasquet A; Allard L; Delmas Y; Contin-Bordes C; Brissaud O; Llanas B; Harambat J
    Nephrol Dial Transplant; 2020 Dec; 35(12):2147-2153. PubMed ID: 31411695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors.
    Le Clech A; Simon-Tillaux N; Provôt F; Delmas Y; Vieira-Martins P; Limou S; Halimi JM; Le Quintrec M; Lebourg L; Grangé S; Karras A; Ribes D; Jourde-Chiche N; Rondeau E; Frémeaux-Bacchi V; Fakhouri F
    Kidney Int; 2019 Jun; 95(6):1443-1452. PubMed ID: 30982675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document.
    Campistol JM; Arias M; Ariceta G; Blasco M; Espinosa L; Espinosa M; Grinyó JM; Macía M; Mendizábal S; Praga M; Román E; Torra R; Valdés F; Vilalta R; Rodríguez de Córdoba S
    Nefrologia; 2015; 35(5):421-47. PubMed ID: 26456110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel aspects of atypical haemolytic uraemic syndrome and the role of eculizumab.
    Verhave JC; Wetzels JF; van de Kar NC
    Nephrol Dial Transplant; 2014 Sep; 29 Suppl 4():iv131-41. PubMed ID: 25165180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eculizumab treatment in severe pediatric STEC-HUS: a multicenter retrospective study.
    Percheron L; Gramada R; Tellier S; Salomon R; Harambat J; Llanas B; Fila M; Allain-Launay E; Lapeyraque AL; Leroy V; Adra AL; Bérard E; Bourdat-Michel G; Chehade H; Eckart P; Merieau E; Piètrement C; Sellier-Leclerc AL; Frémeaux-Bacchi V; Dimeglio C; Garnier A
    Pediatr Nephrol; 2018 Aug; 33(8):1385-1394. PubMed ID: 29572749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement Gene Variants and Shiga Toxin-Producing
    Frémeaux-Bacchi V; Sellier-Leclerc AL; Vieira-Martins P; Limou S; Kwon T; Lahoche A; Novo R; Llanas B; Nobili F; Roussey G; Cailliez M; Ulinski T; Deschênes G; Alberti C; Weill FX; Mariani P; Loirat C
    Clin J Am Soc Nephrol; 2019 Mar; 14(3):364-377. PubMed ID: 30674459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Practical issues in using eculizumab for children with atypical haemolytic uraemic syndrome in the acute phase: A review of four patients.
    Terano C; Ishikura K; Hamada R; Yoshida Y; Kubota W; Okuda Y; Shinozuka S; Harada R; Iyoda S; Fujimura Y; Hamasaki Y; Hataya H; Honda M
    Nephrology (Carlton); 2018 Jun; 23(6):539-545. PubMed ID: 28387984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. STEC-HUS, atypical HUS and TTP are all diseases of complement activation.
    Noris M; Mescia F; Remuzzi G
    Nat Rev Nephrol; 2012 Nov; 8(11):622-33. PubMed ID: 22986360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of complement in Streptococcus pneumoniae-associated haemolytic uraemic syndrome.
    Szilágyi A; Kiss N; Bereczki C; Tálosi G; Rácz K; Túri S; Györke Z; Simon E; Horváth E; Kelen K; Reusz GS; Szabó AJ; Tulassay T; Prohászka Z
    Nephrol Dial Transplant; 2013 Sep; 28(9):2237-45. PubMed ID: 23787556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment and management of children with haemolytic uraemic syndrome.
    Walsh PR; Johnson S
    Arch Dis Child; 2018 Mar; 103(3):285-291. PubMed ID: 28899876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of terminal complement activation in severe Shiga toxin-associated HUS - perfect example for a fast track from bench to bedside.
    Orth-Höller D; Riedl M; Würzner R
    EMBO Mol Med; 2011 Nov; 3(11):617-9. PubMed ID: 21954211
    [No Abstract]   [Full Text] [Related]  

  • 18. Alternative complement pathway hemolytic assays reveal incomplete complement blockade in patients treated with eculizumab.
    Puissant-Lubrano B; Puissochet S; Congy-Jolivet N; Chauveau D; Decramer S; Garnier A; Huart A; Kamar N; Ribes D; Blancher A
    Clin Immunol; 2017 Oct; 183():1-7. PubMed ID: 28647502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of the alternative pathway of complement during the acute phase of typical haemolytic uraemic syndrome.
    Ferraris JR; Ferraris V; Acquier AB; Sorroche PB; Saez MS; Ginaca A; Mendez CF
    Clin Exp Immunol; 2015 Jul; 181(1):118-25. PubMed ID: 25677399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Typical or Atypical Hemolytic Uremic Syndrome and the Use of Eculizumab: 4 Illustrative Cases.
    de Ville de Goyet M; Detaille T; Godefroid N
    J Pediatr Hematol Oncol; 2019 Oct; 41(7):e459-e462. PubMed ID: 30933023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.